Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Candel Therapeutics not addressing metastatic PDAC

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 04, 2024 5:33pm

94 Views

Post# 35971462

RE:RE:RE:RE:RE:RE:Candel Therapeutics not addressing metastatic PDAC

Unlike ONCY's pelareorep, Candel Therapeutics herpes virus OV does NOT have Rare/Orphan designation by the FDA, and therefore would not be eligible for Accelerated Approval, as would ONCY .. which places ONCY years ahead of Candel Therapeutics in terms of gaining marketing approval.

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo